Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146667 | 0.84 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL3149915 | 0.81 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL3216011 | 0.78 | SLC2A1 (0.33) | KCNH2SLC2A1 | |
| SCHEMBL4437596 | 0.75 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL3621094 | 0.75 | KCNH2 (0.44) | KCNH2SLC2A1 | |
| SCHEMBL3215289 | 0.73 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3149833 | 0.72 | KCNH2 (0.43) | KCNH2SLC2A1 | |
| SCHEMBL3153644 | 0.72 | MTNR1A (0.41) | KCNH2SLC2A1 | |
| SCHEMBL3154757 | 0.71 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL3840641 | 0.71 | KCNH2 (0.51) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | KCNH2 784/4885SLC2A1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.